These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8565379)

  • 1. False-positive imaging of In-111 labeled monoclonal antibody conjugate CYT-103 in a patient with metastatic colorectal carcinoma.
    Bhatia M; Baron PL; Alderman DF; Gordon L
    Clin Nucl Med; 1995 Nov; 20(11):979-80. PubMed ID: 8565379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-111 CYT-103 monoclonal antibody imaging in patients with suspected recurrent colorectal cancer.
    Doerr RJ; Herrera L; Abdel-Nabi H
    Cancer; 1993 Jun; 71(12 Suppl):4241-7. PubMed ID: 8508386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoscintigraphy of colorectal carcinoma utilizing 111In-labeled monoclonal antibody conjugate CYT-103.
    Neal CE; Swan TL; Baker MR; Ellis RL; Katterhagen JG
    Gastrointest Radiol; 1991; 16(3):251-5. PubMed ID: 1879645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of OncoScint scan to assess resectability of hepatic metastases from colorectal cancer.
    Su WT; Brachman M; O'Connell TX
    Am Surg; 2001 Dec; 67(12):1200-3. PubMed ID: 11768830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences. Early observations.
    Bohdiewicz PJ; Scott GC; Juni JE; Fink-Bennett D; Wilner F; Nagle C; Dworkin HJ
    Clin Nucl Med; 1995 Mar; 20(3):230-6. PubMed ID: 7750217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of recurrent colorectal carcinoma with In-111 CYT-103 scintigraphy in a patient with nondiagnostic MRI and CT.
    Edlin JP; Kahn D
    Clin Nucl Med; 1994 Nov; 19(11):1004-7. PubMed ID: 7842571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the radiolabeled murine monoclonal antibody, 111In-CYT-103, in the management of colon cancer.
    Petersen BM; Bass BL; Bates HR; Chandeysson PL; Harmon JW
    Am J Surg; 1993 Jan; 165(1):137-42; discussion 142-3. PubMed ID: 8418688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake of In-111 GYK-DTPA B72.3 monoclonal antibody in metastatic squamous cell carcinoma.
    Blend MJ; De La Coates-Johnson R
    Clin Nucl Med; 1994 Oct; 19(10):912-3. PubMed ID: 7805331
    [No Abstract]   [Full Text] [Related]  

  • 9. Multicenter clinical trials of monoclonal antibody B72.3-GYK-DTPA 111In (111In-CYT-103; OncoScint CR103) in patients with colorectal carcinoma.
    Abdel-Nabi HH; Doerr RJ
    Targeted Diagn Ther; 1992; 6():73-88. PubMed ID: 1576351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy.
    Raderer M; Becherer A; Kurtaran A; Angelberger P; Li S; Leimer M; Weinlaender G; Kornek G; Kletter K; Scheithauer W; Virgolini I
    J Nucl Med; 1996 Sep; 37(9):1480-7. PubMed ID: 8790198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Indium 111-labeled antibodies in the detection of colorectal carcinoma].
    Artiko V; Obradović V; Davidović B; Petrović N; Petrović M; Krivokapić Z; Pavlov M; Adanja G; Sobić D; Vlajković M; Pavlović S; Rebić R
    Acta Chir Iugosl; 2003; 50(4):43-6. PubMed ID: 15307496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site of mistletoe injection observed on In-111 OncoScint imaging.
    Choe W
    Clin Nucl Med; 1997 Feb; 22(2):127. PubMed ID: 9031776
    [No Abstract]   [Full Text] [Related]  

  • 13. Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer. Correlation with computed tomography, surgery, histopathology, immunohistology, and human immune response.
    Winzelberg GG; Grossman SJ; Rizk S; Joyce JM; Hill JB; Atkinson DP; Sudina K; Anderson K; McElwain D; Jones AM
    Cancer; 1992 Apr; 69(7):1656-63. PubMed ID: 1551051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in biodistribution of indium-111-and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer.
    Yokoyama K; Carrasquillo JA; Chang AE; Colcher D; Roselli M; Sugarbaker P; Sindelar W; Reynolds JC; Perentesis P; Gansow OA
    J Nucl Med; 1989 Mar; 30(3):320-7. PubMed ID: 2738661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 111In-CYT-103 immunoscintigraphy in ovarian cancer.
    Cannistra SA
    Gynecol Oncol; 1993 Nov; 51(2):292-4. PubMed ID: 8276314
    [No Abstract]   [Full Text] [Related]  

  • 16. In-111-labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma: safety, sensitivity, and preliminary clinical results.
    Abdel-Nabi H; Doerr RJ; Chan HW; Balu D; Schmelter RF; Maguire RT
    Radiology; 1990 Apr; 175(1):163-71. PubMed ID: 2315476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT.
    Collier BD; Abdel-Nabi H; Doerr RJ; Harwood SJ; Olsen J; Kaplan EH; Winzelberg GG; Grossman SJ; Krag DN; Mitchell EP
    Radiology; 1992 Oct; 185(1):179-86. PubMed ID: 1523304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OncoScint CR103 imaging in the surgical management of patients with colorectal cancer.
    Doerr RJ; Abdel-Nabi HH
    Targeted Diagn Ther; 1992; 6():89-109. PubMed ID: 1576352
    [No Abstract]   [Full Text] [Related]  

  • 19. 111In-CYT-103 scanning in recurrent colorectal cancer--does it affect standard management?
    Dominguez JM; Wolff BG; Nelson H; Forstrom LA; Mullan BP
    Dis Colon Rectum; 1996 May; 39(5):514-9. PubMed ID: 8620800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunopharmacokinetics of 111In-CYT-103 in ovarian cancer patients.
    Jusko WJ; Kung LP; Schmelter RF
    Targeted Diagn Ther; 1992; 6():177-90. PubMed ID: 1576345
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.